Risk of Antibody‐Mediated Rejection in Kidney Transplant Recipients With Anti‐HLA‐C Donor‐Specific Antibodies. Issue 6 (7th May 2014)

• Record Type: Journal Article
• Authors: Aubert, O.; Bories, M.‐C.; Suberbielle, C.; Snanoudj, R.; Anglicheau, D.; Rabant, M.; Martinez, F.; Scemla, A.; Legendre, C.; Sberro‐Soussan, R.
• Is Part Of: American journal of transplantation. Volume 14:Issue 6(2014:Jun.)
• Page Start: 1439
• Page End: 1445
• Publication Date: 2014-05-07
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.12709
• Languages: English
• ISSNs: 1600-6135

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ajt12709-sec-0001" sec-type="section"> <p>Anti‐HLA donor‐specific antibodies (DSAs) cause acute and chronic antibody‐mediated rejection (AMR). However, the clinical relevance of anti‐HLA‐C antibodies remains unclear. We evaluated the clinical relevance of the presence of anti‐HLA‐C DSA at day 0 in renal transplant recipients. In this retrospective, case‐controlled study, 608 patients who underwent kidney transplantation between August 2008 and March 2012 were screened for the presence of isolated anti‐HLA‐C DSA at day 0. A total of 22 renal transplant recipients were selected and followed for a period of 1 year. AMR was classified according to the Banff classification. The 22 patients were compared with 88 immunized patients. Acute AMR was diagnosed in six patients (27.3%). The median level of DSA at day 0 was 1179 (530–17 941). The mean fluorescence intensity in the anti‐C group was 4966 (978–17 941) in the AMR group and 981 (530–8012) in the group of patients without AMR. Acute AMR was diagnosed less frequently in the 88 immunized individuals (9.1%) than in the DSA anti‐C group (p = 0.033). The level of DSA at day 0 was predictive for AMR (p = 0.017). Patients with a high level of pretransplant anti‐HLA‐C DSAs are likely to develop acute AMR during the first year after transplantation.</p> </sec> </abstract>